

IN THE SPECIFICATION

At page 1, in the space immediately following the title of the invention, please insert the following priority claim:

-- CROSS-REFERENCE TO RELATED APPLICATIONS

Priority is hereby claimed to co-pending PCT application Serial No. PCT/GB2005/000174, filed 19 January 2005, which claims priority to GB patent application Serial Nos. 0401291.0, filed 21 January 2004, and 0418141.8, filed 13 August 2004. --

Please amend the paragraph at page 2, lines 1-14 to read as follows:

-- Examples of extended release polymers are the cellulose derivatives ethylcellulose and cellulose acetate, the ammoniomethacrylate copolymers (eg Eudragit RS and RL), and polyvinyl acetate. **(Eudragit® is a registered trademark of Röhm GMBH & Co. KG, Darmstadt, Germany, for use in conjunction with coating lacquers for use on medicinal tablets.)** For delayed release, polymers are generally soluble above a threshold pH, which corresponds to the pH of a certain region within the gastrointestinal tract (eg Eudragit L100-55 (pH 5.5) and L100 (6.0) for intestinal targeting and Eudragit S100 (7.0) and P4135 (7.0-7.4) for colonic targeting). In particular, previous attempts at formulating microparticles of Eudragit L100 and Eudragit S100 have been unsuccessful, resulting in particles of poor morphology and control of drug release, and have involved complicated production methods involving homogenisation, careful control of temperature (for production of a good emulsion and/or solvent removal) or rate of addition of surfactant (Goto et al (1986), Morishita et al (1991), Squillante et al (2003)). --